Daiichi Sankyo Company, Limited (TYO:4568)
2,935.50
+55.50 (1.93%)
Sep 25, 2026, 11:30 AM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 574.74B JPY in the quarter ending June 30, 2026, with 21.10% growth. This brings the company's revenue in the last twelve months to 2.22T, up 15.51% year-over-year. In the fiscal year ending March 31, 2026, Daiichi Sankyo Company had annual revenue of 2.12T with 12.55% growth.
Revenue (ttm)
2.22T
Revenue Growth
+15.51%
P/S Ratio
2.36
Revenue / Employee
110.22M
Employees
20,171
Market Cap
5.24T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.12T | 236.79B | 12.55% |
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.62T |
| Otsuka Holdings | 2.62T |
| Astellas Pharma | 2.27T |
| Chugai Pharmaceutical | 1.34T |
| Terumo | 1.18T |
| Olympus | 1.04T |
| HOYA Corporation | 983.64B |
| Eisai | 857.06B |
Daiichi Sankyo Company News
- 15 hours ago - Malaysia's IHH's unit appeals Tokyo court's rejection of Daiichi Sankyo damages claim - Reuters
- 3 days ago - AstraZeneca: CHMP Recommends Enhertu For Approval In The EU - Nasdaq
- 6 days ago - Daiichi Sankyo Gets Japan Approval For Enhertu, Datroway In First-Line Metastatic Breast Cancer - Nasdaq
- 7 days ago - AstraZeneca's Enhertu Gets NICE Recommendation For HER2 Low Metastatic Breast Cancer - Nasdaq
- 7 days ago - Fortis moves Supreme Court against Delhi High Court order - The Times of India
- 10 days ago - AstraZeneca's Enhertu Improves PFS By 6 Months In First-Line HER2-Mutant NSCLC; Daiichi Stock Up - Nasdaq
- 14 days ago - Malaysia's IHH's unit loses Tokyo court case against Daiichi Sankyo over Fortis deal - Reuters
- 23 days ago - AstraZeneca And Daiichi Sankyo Gain EU Nod For Enhertu Plus Pertuzumab In HER2+ Breast Cancer - Nasdaq